These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31098693)

  • 1. Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer.
    Shikama A; Minaguchi T; Takao W; Hosokawa Y; Nishida K; Tasaka N; Akiyama A; Sakurai M; Ochi H; Satoh T
    Int J Clin Oncol; 2019 Oct; 24(10):1256-1263. PubMed ID: 31098693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome.
    Hall M; Savvatis K; Nixon K; Kyrgiou M; Hariharan K; Padwick M; Owens O; Cunnea P; Campbell J; Farthing A; Stumpfle R; Vazquez I; Watson N; Krell J; Gabra H; Rustin G; Fotopoulou C
    Ann Surg Oncol; 2019 Sep; 26(9):2943-2951. PubMed ID: 31243666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.
    Zang RY; Harter P; Chi DS; Sehouli J; Jiang R; Tropé CG; Ayhan A; Cormio G; Xing Y; Wollschlaeger KM; Braicu EI; Rabbitt CA; Oksefjell H; Tian WJ; Fotopoulou C; Pfisterer J; du Bois A; Berek JS
    Br J Cancer; 2011 Sep; 105(7):890-6. PubMed ID: 21878937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
    Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
    Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit.
    Bacalbasa N; Dima S; Brasoveanu V; David L; Balescu I; Purnichescu-Purtan R; Popescu I
    World J Surg Oncol; 2015 Aug; 13():235. PubMed ID: 26243426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
    Musella A; Marchetti C; Palaia I; Perniola G; Giorgini M; Lecce F; Vertechy L; Iadarola R; De Felice F; Monti M; Muzii L; Angioli R; Panici PB
    Ann Surg Oncol; 2015 Dec; 22(13):4211-6. PubMed ID: 25801357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift.
    Papadia A; Bellati F; Ditto A; Bogani G; Gasparri ML; Di Donato V; Martinelli F; Lorusso D; Benedetti-Panici P; Raspagliesi F
    Ann Surg Oncol; 2015 Dec; 22(13):4204-10. PubMed ID: 25777095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
    Zhao D; Wu LY; Wang XB; Li XG
    Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
    Risum S; Loft A; Engelholm SA; Høgdall E; Berthelsen AK; Nedergaard L; Lundvall L; Høgdall C
    Int J Gynecol Cancer; 2012 Sep; 22(7):1163-9. PubMed ID: 22810969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers.
    Raspagliesi F; Bogani G; Ditto A; Martinelli F; Chiappa V; Borghi C; Scaffa C; Morano F; Maltese G; Lorusso D
    Ann Surg Oncol; 2017 Oct; 24(11):3396-3405. PubMed ID: 28795373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
    Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.
    Tian WJ; Chi DS; Sehouli J; Tropé CG; Jiang R; Ayhan A; Cormio G; Xing Y; Breitbach GP; Braicu EI; Rabbitt CA; Oksefjell H; Fotopoulou C; Meerpohl HG; du Bois A; Berek JS; Zang RY; Harter P
    Ann Surg Oncol; 2012 Feb; 19(2):597-604. PubMed ID: 21732142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
    Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
    Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
    Fotopoulou C; Richter R; Braicu IE; Schmidt SC; Neuhaus P; Lichtenegger W; Sehouli J
    Ann Surg Oncol; 2011 Jan; 18(1):49-57. PubMed ID: 20697821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.